1. Cytomegalovirus infection and disease after liver transplantation. An overview.
- Author
-
Stratta RJ, Shaeffer MS, Markin RS, Wood RP, Langnas AN, Reed EC, Donovan JP, Woods GL, Bradshaw KA, and Pillen TJ
- Subjects
- Cytomegalovirus pathogenicity, Cytomegalovirus Infections epidemiology, Cytomegalovirus Infections prevention & control, Humans, Incidence, Liver microbiology, Risk Factors, Surgical Wound Infection epidemiology, Surgical Wound Infection prevention & control, Terminology as Topic, Transplantation, Homologous, Cytomegalovirus Infections diagnosis, Liver Transplantation, Surgical Wound Infection diagnosis
- Abstract
Cytomegalovirus is the single most important pathogen in clinical transplantation. Although much progress has been made in our understanding of the molecular biology and epidemiology of CMV infection and in our ability to diagnosis and treat CMV disease, it remains a major cause of morbidity but is no longer a major cause of mortality after liver transplantation. Risk factors for CMV disease after liver transplantation include donor and recipient serologic status, the use of antilymphocyte therapy, and retransplantation. CMV disease occurs early after transplantation, and the most frequent site of disease is the hepatic allograft. We have treated 79 patients with intravenous ganciclovir, with ultimate control of disease achieved in 69 patients (87.3%). Preliminary results using intravenous immunoglobulin and oral acyclovir for CMV prophylaxis in high-risk patients have been encouraging. In addition to producing clinical syndromes. CMV may have direct immunologic effects and is a marker of the net state of immunosuppression.
- Published
- 1992
- Full Text
- View/download PDF